Morgans assesses there is an opportunity in Micro-X, when comparing its technology and commercial outcomes with the US-based Nanox which operates in a similar segment.

Both are developing technology to militarise x-rays, with applications not only in hospitals but also in security and military settings.

Micro-X has also received Australia's Therapeutic Goods Authority approval for the Rover and the company estimates the market size is $10m. Morgans maintains a positive stance on the stock and the Speculative Buy rating is maintained. Target is $0.58.

Sector: Health Care Equipment & Services.

Target price is $0.58.Current Price is $0.30. Difference: $0.28 - (brackets indicate current price is over target). If MX1 meets the Morgans target it will return approximately 48% (excluding dividends, fees and charges - negative figures indicate an expected loss).

© 2021 Acquisdata Pty Ltd., source FN Arena